^
Association details:
| Biomarker: | MYC overexpression + BCL2 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + luxeptinib (CG-806) (BTK inhibitor, FLT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 4225: CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas
Published date:
05/15/2020
Excerpt:
Double/triple-hit lymphomas (DHL/THL, harboring concurrent MYC, BCL2 and/or BCL6 rearrangements) and double-expressor lymphomas (DEL, with MYC/BCL2 co-overexpression without underlying rearrangements) account for 7-12% and 20-30% of diffuse large B-cell lymphomas (DLBCLs)...In the DEL cell line U2933, CG-806 and venetoclax had similar potency as single agents (IC50 1.6 µM); when combined, the IC50 was markedly improved to 0.05 µM.
DOI:
10.1158/1538-7445.AM2020-4225